North Star Asset Management Inc. Takes $9.83 Million Position in Prestige Consumer Healthcare Inc. $PBH

North Star Asset Management Inc. bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 2nd quarter, Holdings Channel reports. The fund bought 208,000 shares of the company’s stock, valued at approximately $9,832,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at approximately $370,187,000. Dimensional Fund Advisors LP lifted its position in Prestige Consumer Healthcare by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock worth $158,414,000 after acquiring an additional 91,710 shares during the period. State Street Corp grew its stake in shares of Prestige Consumer Healthcare by 1.4% in the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after purchasing an additional 27,721 shares during the last quarter. Morgan Stanley grew its stake in shares of Prestige Consumer Healthcare by 6.3% in the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after purchasing an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 5.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after purchasing an additional 35,126 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.7%

NYSE:PBH opened at $51.27 on Friday. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The stock has a fifty day moving average price of $50.11 and a two-hundred day moving average price of $54.64. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same period in the previous year, the firm earned $0.90 EPS. The business’s revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current fiscal year.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
• Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
• Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
• Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PBH shares. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).